Relevance of breast cancer subtypes for magnetic resonance imaging response monitoring during neoadjuvant chemotherapy

Clinical and Translational Oncology

Volumn 14, Issue 6, 2012, Pages 486-488

  Gómez Raposo, Cesar ^a   Andreu, Mónica ^a   Suárez García, Inés ^a   Esteban, M Isabel ^a   Carballo, Mar ^a   Sereno Moyano, María F ^a   Vázquez Osorio, José L ^a   Heras, Javier ^a   Zambrana Tévar, Francisco ^a   Pelayo, Eva ^a   López Gómez, Miriam ^a   García De Santiago, Clara ^a   Merino Salvador, María ^a   Casado, Enrique ^a  

^a HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

Author keywords

Breast cancer subtypes; Magnetic resonance imaging; Neoadjuvant chemotherapy; Predictive factors

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COMPARATIVE STUDY; ER NEGATIVE BREAST CANCER; ER POSITIVE BREAST CANCER; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HER2 NEGATIVE BREAST CANCER; HER2 POSITIVE BREAST CANCER; HUMAN; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE NEU; PATHOLOGICAL COMPLETE RESPONSE; PREDICTIVE VALIDITY; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH;

BREAST NEOPLASMS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; NEOADJUVANT THERAPY; NEOPLASM STAGING; RECEPTOR, ERBB-2;

EID: 84864704230     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0828-9     Document Type: Article

References (5)

1. Wolmark N, Wang J, Mamounas E et al (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30:96-102
2. Rastogi P, Anderson SJ, Bear HD et al (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26:778-785
3. Symmans WF, Peintinger F, Hatzis C et al (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414-4422
4. Padhani AR, Hayes C, Assersohn L et al (2006) Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology 239:361-374
5. Loo CE, Straver ME, Rodenhuis S et al (2011) Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol 29:660-666